David Hansen, MBA, joins Hometown Health to continue to serve future generations and improve the health and well-being of Nevadans Renown Health and Hometown Health are excited to announce David Hansen, MBA, is joining Hometown Health as its Chief Executive Officer (CEO). In his role as CEO, Hansen will oversee Hometown Health, contributing to its growth to ensure the not-for-profit company is here for generations to come and to assist Renown in developing new care models that will deliver healthcare that is both accessible and affordable. “We are pleased to welcome such an experienced and talented leader like David to our organization and to northern Nevada,” said Tony Slonim, MD, D.Ph., President and CEO, Renown Health. “As CEO of Hometown Health, David will continue to foster a culture of caring and excellence, while ensuring wide-ranging medical coverage and great customer service to Hometown Health’s more than 138,000 members statewide.” Hansen has spent the previous twenty years of his career working for UnitedHealthcare, a health insurance company based out of Minnetonka, Minnesota. During his time at UnitedHealthcare, Hansen held various roles including chief financial officer of clinical & network services, west region president of network & provider services, chief executive officer of the California Health Plan and chief executive officer of the Pacific Northwest Health Plan. He has also served in executive roles with PacifiCare and TransAmerica Occidental Life and began his career in the audit and management consulting practice of Deloitte & Touche. “Choosing healthcare coverage is one of the most important decisions people make. I am excited to begin my work with Hometown Health and Renown to help our members receive the quality coverage to enhance their health and well-being,” said Hansen. “Hometown Health is such a community-focused organization and I look forward to being a part of a team that gives back to improve the health and wellbeing of the communities we serve. ”David has an MBA in Finance and Business Policy from the University of Chicago, and a BA in Economics and Business from the University of California, Los Angeles. About Hometown Health Established in 1988, Hometown Health is the insurance division of Renown Health and is Northern Nevada’s largest locally-owned, not-for-profit health insurance company. Providing wide-ranging medical coverage and great service to members, Hometown Health represents a philosophy of health care that emphasizes active partnerships between members and physicians. For more information, call 775-982-3000 or visit www.hometownhealth.com. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.
Suzanne Hendery, MA, APR of Renown Health selected as 2020 Medigy HITMC Award Winner. Every year, the Healthcare and IT Marketing Community (HITMC) honors the individuals and organizations who distinguished themselves over the past year. Nominations for the Awards are reviewed by a selection committee made up of industry veterans and only three are chosen as Honorees in each category. A panel of judges then evaluates the Honorees and a winner is chosen. Suzanne Hendery, Chief Marketing, Public Affairs & Community Impact Officer for Renown Health has been selected as the 2020 ‘Marketing Person of the Year.” “Suzanne Hendery of Renown Health is a deserving winner of a 2020 Medigy HITMC Award” said John Lynn, Chief Editor and Founder at Healthcare Scene, the company behind HITMC. “Together, the 2020 Award Winners are a shining example of the best in healthcare marketing. It is truly inspiring to see what happens when bright, passionate people work together.” The 2020 Medigy HITMC Awards are a celebration of outstanding achievement in marketing, PR and communications for healthcare and Health IT. It is a chance for the Healthcare and IT Marketing Community (HITMC) to come together and acknowledge the hard work and efforts of individuals, Health IT companies, healthcare providers and agencies. “We at Renown Health are so proud of Suzanne and the entire Marketing & Communications team. They tell the stories of our health care heroes, engage with our community, and use communications to encourage people to improve their health and well-being,” said Tony Slonim, MD, DrPH, president and CEO of Renown Health. Ms. Hendery says, “Being able to distill the essence of our organization down to 2 words- ‘hope’ and ‘determination’-is something that brings me such pride. I feel honored – and humbled – that Jim DeVolld and Rob Winkel of the Renown Board of Trustees; Dr. Tony Slonim, our CEO; and our lead physicians, nurses, team members and partners, all came together with our community to build the “Fight the Good Fight” campaign. This work gives us all the inspirational message of hope and determination during such an important time in our history.” Suzanne Hendery is the Chief Marketing, Communications & Community Impact Officer for Renown Health in Reno. Ms. Hendery earned her MA from the University of Connecticut, is a lecturer at Harvard University, a member of the American Marketing Association Health Care Executive Board, a member of the Public Relations Society of America, and serves on the Board of the Society for Healthcare Strategy and Market Development. About The HITMC Awards HITMC is a community – bound together by a passion for and a love of PR, communications and marketing in healthcare and Health IT. The central idea behind HITMC is to bring together all the smart, innovative and hard- working healthcare professionals so that we can learn from each other. We enable this by creating a culture where sharing, mutual respect and lifting each other up is the norm. The annual HITMC Awards are an embodiment of this ethos. They are meant to celebrate the best individuals and organizations who have elevated healthcare marketing, PR and communications in the past year. For more information, visit www.hitmc.com/awards About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.
Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.” About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH. About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org and follow Dr. Tony Slonim on Twitter @RenownCEOTonyMD. About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.Additional Media Contact:Sung Lee, Investors 650-524-7792Arran Attridge, Media 650-425-8975